December 18, 2020   USA
Endocrine News: Potential Type 1 Diabetes Vaccine Shows Promise

Earlier this fall, Phase IIb topline results of the DIAGNODE-2 trial demonstrated a potential type 1 diabetes vaccine GAD-alum — an immunomodulating antigen-specific therapy – had a highly significant and clinically relevant effect in genetically defined subgroups of individuals with the disease. Diamyd Medical is supporting the trials and developing the drug candidate as Diamyd®.

Read the article here

Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.

Order GAD for preclinical research